老年患者使用索利那新：一项观察性研究的结果，该研究测量了疗效、耐受性和认知影响。
Solifenacin in the Elderly: Results of an Observational Study Measuring Efficacy, Tolerability and Cognitive Effects.
作者信息
Hampel Christian, Betz Dietmar, Burger Maximilian, Nowak Christoph, Vogel Monika
机构信息
Department of Urology, University Medical Center of the Johannes-Gutenberg University, Mainz, Germany.
出版信息
Urol Int. 2017;98(3):350-357. doi: 10.1159/000455257. Epub 2017 Feb 2.
INTRODUCTION
The study aimed to evaluate the efficacy and safety of solifenacin in older patients with overactive bladder (OAB).
MATERIALS AND METHODS
Observational data on patients aged ≥70 years and the prescribed flexible dose of solifenacin for OAB were collected at 294 offices of German general practitioners. Baseline and week 12 data included type and severity of OAB symptoms, adverse events, quality of life, and change in cognitive function per Mini Mental State Examination (MMSE).
RESULTS
Mean age of 774 patients was 78 ± 6 years. A decrease was observed in all OAB symptoms including a reduction of urinary urgency and micturition, each by 4 episodes per 24 h. No change in mean MMSE scores was apparent at week 12. Adverse events and treatment discontinuations were low at 5.8 and 0.5%, respectively.
CONCLUSION
Solifenacin was well-tolerated while OAB symptoms declined at week 12. No relevant effect of solifenacin on cognitive function was observed in this elderly population.
引言
本研究旨在评估索利那新对老年膀胱过度活动症（OAB）患者的疗效和安全性。
材料与方法
在德国294家全科医生诊所收集了年龄≥70岁患者的观察数据以及为治疗OAB而开具的索利那新灵活剂量。基线和第12周的数据包括OAB症状的类型和严重程度、不良事件、生活质量以及根据简易精神状态检查表（MMSE）得出的认知功能变化。
结果
774例患者的平均年龄为78±6岁。观察到所有OAB症状均有所减轻，包括尿急和排尿次数减少，每24小时各减少4次。在第12周时，MMSE平均得分无明显变化。不良事件和停药率较低，分别为5.8%和0.5%。
结论
索利那新耐受性良好，在第12周时OAB症状有所减轻。在该老年人群中未观察到索利那新对认知功能有相关影响。
Zotero 插件